<DOC>
	<DOCNO>NCT01450696</DOCNO>
	<brief_summary>This randomize , open-label , multicenter , international Phase IIIb study compare efficacy safety two Herceptin dose regimen combination cisplatin/capecitabine chemotherapy participant HER2-positive metastatic gastric gastro-esophageal junction adenocarcinoma . Participants receive prior treatment metastatic disease randomize receive Herceptin intravenously either 8-milligram per kilogram ( mg/kg ) load dose follow 6 mg/kg every 3 week ( q3w ) standard care 8-mg/kg loading dose follow 10 mg/kg q3w disease progression . Capecitabine administer 6 cycle dose 800 milligram per meter-squared ( mg/m^2 ) orally twice day Days 1 14 3-week cycle , cisplatin administer intravenously 6 cycle dose 80 mg/m^2 Day 1 3-week cycle . Herceptin continue disease progression occur .</brief_summary>
	<brief_title>A Study Herceptin ( Trastuzumab ) Combination With Cisplatin/Capecitabine Chemotherapy Participants With Human Epidermal Growth Factor Receptor 2 ( HER2 ) -Positive Metastatic Gastric Gastro-Esophageal Junction Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Histologically confirm adenocarcinoma stomach gastroesophageal junction metastatic disease document involve least liver lung Measurable disease accord RECIST Version 1.1 nonmeasurable evaluable disease At least 2 organ involve metastatic gastric tumor ( include least lung liver ) addition site primary tumor , metastasis distant lymph node , peritoneal metastasis , malignant pleural effusion may count `` organ '' context HER2positive primary metastatic tumor assess central laboratory Adequate renal function ( creatinine clearance great equal ( â‰¥ ) 45 milliliter per minute [ mL/min ] ) Eastern Cooperative Oncology Group ( ECOG ) performance status 2 Previous chemotherapy locally advance metastatic disease Prior gastrectomy ( partial total ) underlie malignant disease investigation Prior therapy antiHER2 agent and/or platinumbased chemotherapeutic agent Residual relevant toxicity result previous therapy Lack physical integrity upper gastrointestinal tract malabsorption syndrome ( jejunostomy probe gastric jejunostomy tube ) may impair ability administer absorb capecitabine Current ( significant uncontrolled ) gastrointestinal bleed Other malignancy within last 5 year , except carcinoma situ cervix basal squamous cell carcinoma skin History document congestive heart failure , angina pectoris require medication , electrocardiogram ( ECG ) evidence transmural myocardial infraction , poorly control hypertension , clinically significant valvular heart disease , highrisk uncontrollable arrhythmias Baseline leave ventricular ejection fraction ( LVEF ) less ( &lt; ) 50 % , document echocardiography , multiplegated radionuclide angiography ( MUGA ) scan , cardiac magnetic resonance imaging ( MRI ) Chronic highdose corticosteroid therapy History clinical evidence brain metastasis Pregnant woman Active infection human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C , HIVseropositive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>